Abstract
Whereas CD103+ dendritic cells (DCs) were previously considered to be a minor DC subset in kidney disease, we and others have proven that they have a major role. Flt3 ligand is a growth factor essential for CD103+ DC development and survival. Flt3 inhibitors are currently used for cancer treatment, and potentially could be repurposed to treat kidney disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
